Page 66 - Read Online

Zhang et al. Neuroimmunol Neuroinflammation 2019;6:8 I http://dx.doi.org/10.20517/2347-8659.2019.06 Page 15 of 16

multiple sclerosis: results from a multicenter study in German speaking countries. Eur J Neurol 2010;17:31-7.
144. Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim
observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190-7.
145. Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple
sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord
2017;11:25-31.
146. Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-
remitting multiple sclerosis. PLoS One 2013;8:e53297.
147. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci
2015;16:16414-39.
148. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, et al. Alemtuzumab for patients with relapsing multiple sclerosis after
disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39.
149. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients
with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
150. Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety
and efficacy. J Neurol Neurosurg Psychiatry. 2015;86:208-15.
151. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis.
N Engl J Med 2017;376:209-20.
152. Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2,
randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87.
153. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis.
N Engl J Med 2017;376:221-34.
154. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple
sclerosis. N Engl J Med 2010;362:416-26.
155. Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, et al. Effect of parenteral cladribine on relapse rates in patients with
relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult Scler 2009;15:767-70.
156. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, et al. Siponimod versus placebo in secondary progressive multiple sclerosis
(EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018;391:1263-73.
157. Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, et al. Safety and efficacy of Siponimod (BAF312) in patients with relapsing-
remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 2016;73:1089-98.
158. Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD):
an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67.
159. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F, et al. Comparison of the efficacy of azathioprine and rituximab in
neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017;264:2003-9.
160. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-
label, phase I trial. Ann Neurol 2008;63:395-400.
161. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a
52-week phase II trial. Neurology 2010;74:1860-7.
162. Hawker K, O’ Connor P, Freedman MS, Calabresi PA, Antel J, et al. Rituximab in patients with primary progressive multiple sclerosis:
results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-71.
163. Huang TL, Lin KH, Wang JK, Tsai RK. Treatment strategies for neuromyelitis optica. Ci Ji Yi Xue Za Zhi 2018;30:204-8.
164. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and
azathioprine. Neurology 1998;51:1219-20.
165. Bichuetti DB, Perin MMM, Souza NA, Oliveira EML. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult
Scler 2018: doi: 10.1177/1352458518776584.
166. Qiu W, Kermode AG, Li R, Dai Y, Wang Y, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis
optica. J Clin Neurosci 2015;22:1178-82.
167. Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, et al. Azathioprine versus beta interferons for relapsing-remitting
multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One 2014;9:e113371.
168. Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, et al. Mycophenolate mofetil, an inhibitor of inosine monophosphate
dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004;107:63-8.
169. Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015;351:31-5.
170. Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum
disorder. JAMA Neurol 2014;71:1372-8.
171. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, et al. Treatment of neuromyelitis optica with mycophenolate
mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-33.
172. Huang Q, Wang J, Zhou Y, Yang H, Wang Z, et al. Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum
disorders: a prospective multicenter study in South China. Front Immunol 2018;9:2066.
173. Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. J Neurol Sci 2003;24:S265-7.
174. Paul F, Dörr J, Würfel J, Vogel HP, Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J
Neurol Neurosurg Psychiatry 2007;78:198-200.
175. Stettner M, Gross CC, Mausberg AK, Pul R, Junker A, et al. A fatal case of daclizumab-induced liver failure in a patient with MS.
Neurol Neuroimmunol Neuroinflamm 2019;6:e539.